Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, van de Werf F, Verheugt F, Armstrong PW. Taher T, et al. Among authors: wallentin l. J Am Coll Cardiol. 2004 Jul 7;44(1):38-43. doi: 10.1016/j.jacc.2004.03.041. J Am Coll Cardiol. 2004. PMID: 15234403 Free article. Clinical Trial.
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Kereiakes DJ, et al. Among authors: wallentin l. Am Heart J. 2002 Oct;144(4):615-24. doi: 10.1067/mhj.2002.124405. Am Heart J. 2002. PMID: 12360156 Review.
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L, Bergstrand L, Dellborg M, Fellenius C, Granger CB, Lindahl B, Lins LE, Nilsson T, Pehrsson K, Siegbahn A, Swahn E. Wallentin L, et al. Eur Heart J. 2003 May;24(10):897-908. doi: 10.1016/s0195-668x(03)00006-x. Eur Heart J. 2003. PMID: 12714021 Clinical Trial.
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Circulation. 2003 Jul 22;108(3):275-81. doi: 10.1161/01.CIR.0000079170.10579.DC. Epub 2003 Jul 7. Circulation. 2003. PMID: 12847065 Clinical Trial.
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: wallentin l. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
James SK, Siegbahn A, Armstrong P, Barnathan E, Califf R, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Am Heart J. 2004 Feb;147(2):267-74. doi: 10.1016/j.ahj.2003.09.014. Am Heart J. 2004. PMID: 14760324 Clinical Trial.
845 results